CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017

3.2.2.1. Top Winning Strategies, By Year, 2014-2017*
3.2.2.2. Top Winning Strategies, By Development, 2014-2017* (%)
3.2.2.3. Top Winning Strategies, By Company, 2014-2017*

3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Surge in incidence of gynecological cancers
3.4.1.2. Growing importance of targeted drug therapies
3.4.1.3. Increase in investment from government, public, and private sector

3.4.2. Restraints

3.4.2.1. High cost of drug development and threat of failure
3.4.2.2. Adverse effects of cancer drug therapy

3.4.3. Opportunities

3.4.3.1. Advancement of cancer drugs research
3.4.3.2. Personalized medicine approach

3.5. CLINICAL TRIALS

CHAPTER 4 GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CHEMOTHERAPY

4.2.1. Key market trends growth factors and opportunities
4.2.2. Market size and forecast

4.3. TARGETED THERAPY

4.3.1. Key market trends growth factors and opportunities
4.3.2. Market size and forecast

4.4. HORMONAL THERAPY

4.4.1. Key market trends growth factors and opportunities
4.4.2. Market size and forecast

CHAPTER 5 GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. UTERINE CANCER

5.2.1. Market size and forecast

5.3. OVARIAN CANCER

5.3.1. Market size and forecast

5.4. VAGINAL & VULVAR CANCER

5.4.1. Market size and forecast

5.5. CERVICAL CANCER

5.5.1. Market size and forecast

CHAPTER 6 GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends growth factors & opportunities
6.2.2. Market size & forecast

6.2.2.1. U.S.

6.2.2.1.1. U.S. gynecological cancer drugs market by therapeutic modality
6.2.2.1.2. U.S. gynecological cancer drugs market by indication

6.2.2.2. Canada

6.2.2.2.1. Canada gynecological cancer drugs market by therapeutic modality
6.2.2.2.2. Canada gynecological cancer drugs market by indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico gynecological cancer drugs market by therapeutic modality
6.2.2.3.2. Mexico gynecological cancer drugs market by indication

6.2.3. North America gynecological cancer drugs market by therapeutic modality
6.2.4. North America gynecological cancer drugs market by indication

6.3. EUROPE

6.3.1. Key market trends growth factors & opportunities
6.3.2. Market size & forecast

6.3.2.1. Germany

6.3.2.1.1. Germany gynecological cancer drugs market by therapeutic modality
6.3.2.1.2. Germany gynecological cancer drugs market by indication

6.3.2.2. France

6.3.2.2.1. France gynecological cancer drugs market by therapeutic modality
6.3.2.2.2. France gynecological cancer drugs market by indication

6.3.2.3. UK

6.3.2.3.1. UK gynecological cancer drugs market by therapeutic modality
6.3.2.3.2. UK gynecological cancer drugs market by indication

6.3.2.4. Italy

6.3.2.4.1. Italy gynecological cancer drugs market by therapeutic modality
6.3.2.4.2. Italy gynecological cancer drugs market by indication

6.3.2.5. Spain

6.3.2.5.1. Spain gynecological cancer drugs market by therapeutic modality
6.3.2.5.2. Spain gynecological cancer drugs market by indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe gynecological cancer drugs market by therapeutic modality
6.3.2.6.2. Rest of Europe gynecological cancer drugs market by indication

6.3.3. Europe gynecological cancer drugs market by therapeutic modality
6.3.4. Europe gynecological cancer drugs market by indication

6.4. ASIA-PACIFIC

6.4.1. Key market trends growth factors & opportunities
6.4.2. Market size & forecast

6.4.2.1. Japan

6.4.2.1.1. Japan gynecological cancer drugs market by therapeutic modality
6.4.2.1.2. Japan gynecological cancer drugs market by indication

6.4.2.2. China

6.4.2.2.1. China gynecological cancer drugs market by therapeutic modality
6.4.2.2.2. China gynecological cancer drugs market by indication

6.4.2.3. India

6.4.2.3.1. INDIA gynecological cancer drugs market by therapeutic modality
6.4.2.3.2. INDIA gynecological cancer drugs market by indication

6.4.2.4. Australia

6.4.2.4.1. Australia gynecological cancer drugs market by therapeutic modality
6.4.2.4.2. Australia gynecological cancer drugs market by indication

6.4.2.5. South Korea

6.4.2.5.1. South Korea gynecological cancer drugs market by therapeutic modality
6.4.2.5.2. South Korea gynecological cancer drugs market by indication

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.2.6.2. Rest of Asia-Pacific gynecological cancer drugs market by indication

6.4.3. Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.4. Asia-Pacific gynecological cancer drugs market by indication

6.5. LAMEA

6.5.1. Key market trends growth factors & opportunities
6.5.2. Market size & forecast

6.5.2.1. Brazil

6.5.2.1.1. Brazil gynecological cancer drugs market by therapeutic modality
6.5.2.1.2. Brazil gynecological cancer drugs market by indication

6.5.2.2. South Africa

6.5.2.2.1. South Africa gynecological cancer drugs market by therapeutic modality
6.5.2.2.2. South Africa gynecological cancer drugs market by indication

6.5.2.3. Saudi Arabia

6.5.2.3.1. Saudi Arabia gynecological cancer drugs market by therapeutic modality
6.5.2.3.2. Saudi Arabia gynecological cancer drugs market by indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA gynecological cancer drugs market by therapeutic modality
6.5.2.4.2. Rest of LAMEA gynecological cancer drugs market by indication

6.5.3. LAMEA gynecological cancer drugs market by therapeutic modality
6.5.4. LAMEA gynecological cancer drugs market by indication

CHAPTER 7 COMPANY PROFILES

7.1. APOTEX INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio

7.2. ASTRAZENECA PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BRISTOL-MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. F. HOFFMANN-LA ROCHE LTD

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. GLAXOSMITHKLINE PLC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. MERCK & CO., INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVARTIS AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. PFIZER INC

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance